VF in the News

FDA Approves Otezla®for the Treatment of Oral Ulcers in Behcet’s Disease

Celgene Corporation announced on July 19 that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behcet’s disease. Otezla, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only…...

Read more

Dr. Sebastian E. Sattui Receives 2019 VCRC-VF Fellowship Award

Sebastian Sattui, MD It was during a medical clerkship that Sebastian Sattui, MD, first recognized the complexity of vasculitis, and the profound impact the disease has on patients’ lives. He had encountered a patient with EGPA (eosinophilic granulomatosis with polyangiitis) for the first time. “I will always remember the patient’s…...

Read more

VF Celebrates Mission Milestone: Funds 50th Research Study

Recently, the Vasculitis Foundation (VF) reached an organizational milestone that secured its legacy as one of the world’s largest private funding sources for research covering the broad spectrum of the vasculitides. With two new research grants issued in February 2019, the VF Research Program has now funded 50 research studies…...

Read more